Strides Pharma Science Reports Q1 FY27 Results with Consolidated Profit of Rs 1,654.93 Million

Strides Pharma Science Reports Q1 FY27 Results with Consolidated Profit of Rs 1,654.93 Million​

Strides Pharma Science Limited has released its unaudited financial results for the first quarter ending June 30, 2026, showing strong performance across both consolidated and standalone segments. The company reported a profit attributable to owners of the company of Rs 1,654.93 million in its consolidated results.

The consolidated statement reflects significant revenue from operations and notable exceptional gains derived from corporate restructuring activities.

Consolidated Financial Highlights (Q1 FY27)

Total income from continuing operations stood at Rs 12,702.97 million for the three months ended June 30, 2026. This includes revenue of Rs 12,654.07 million and other income of Rs 48.90 million. The company reported total expenses amounting to Rs 11,325.93 million. Profit before tax was recorded at Rs 2,009.01 million, resulting in a profit for the period attributable to owners of the Company of Rs 1,654.93 million.

For the quarter ended June 30, 2026, the Group's share of net loss after tax and total comprehensive loss from associates and joint ventures stood at (Rs 12.85) million.

Standalone Performance

In standalone terms, Strides Pharma Science Limited reported revenue from operations totaling Rs 5,826.48 million for the same period. Total income, comprising operational and other income, was reported at Rs 5,841.23 million. After incurring total expenses of Rs 5,757.66 million, the company recorded a profit before tax of Rs 847.58 million. The net profit for the quarter attributable to owners amounted to Rs 729.28 million.

Operational and Corporate Updates

The company noted that its Chief Operating Decision Maker (CODM) evaluates business performance as a single "Pharmaceutical" segment, which encompasses development, manufacture, and commercialization of pharmaceutical products other than biological drugs.

Regarding corporate transactions, the Board of Directors proposed a final dividend of Rs 5 per equity share on May 18, 2026. Furthermore, upon completion of a transaction involving the dilution of its stake in Pivot Path, Strides Pharma Science recognized a net gain of Rs 764.01 million, which was booked as an exceptional item in the financial results.

The company also noted provisions related to product withdrawals and settlements for certain products across various periods, including provision for sales return related to Ranitidine at Rs 14.32 million for the quarter ended June 30, 2026, and a provision of Rs 95.78 million towards recall and settlement costs for testosterone during the same period.

Key Financial Data: Strides Pharma Science Limited​

(All figures in Million Rupees)

STAR Stock Price Movement​

As of 12:45 PM, shares of Strides Pharma Science Limited are slipping by 0.85% in live trading, currently trading at ₹1058.7. The stock has seen a total traded volume of 337,741 shares as the market continues to track pharmaceutical stocks.